University Of Miami

SAN DIEGO — Patients with relapsed large B-cell lymphoma who achieved a complete remission had a reduced relapse rate and improved PFS with autologous transplant, according to study findings presented at ASH Annual Meeting and Exposition.

Reduced-intensity haploidentical-bone marrow transplant showed durable donor engraftment at 2-years follow-up with low mortality among adults with severe sickle cell disease, according to study results.

Revumenib proved safe and effective among pediatric and adult patients with relapsed or refractory KMT2Ar acute myeloid leukemia and acute lymphoid leukemia, according to study results presented at ASH Annual Meeting and Exhibition.

SAN DIEGO — Navitoclax added to ruxolitinib led to a significant improvement in spleen volume reduction compared with placebo among patients with untreated myelofibrosis, study results presented at ASH Annual Meeting and Exposition showed.

SAN DIEGO — A combination of targeted therapies used for a response-directed duration significantly improved outcomes compared with chemoimmunotherapy for fit patients with untreated chronic lymphocytic leukemia, according to study results.

By 2023, there will be about 4 million Latino cancer survivors in the United States, representing approximately one-fifth of the survivorship population.

Misdiagnoses of myelodysplastic syndrome appeared common among patients included in MDS Natural History Study, according to study results published in Blood Advances.

The FDA approved quizartinib for use in combination with standard chemotherapy for treatment of patients with newly diagnosed acute myeloid leukemia with FLT3 internal tandem duplication mutations.

CHICAGO — A chemotherapy de-escalation strategy involving dual HER2 blockade resulted in high rates of 3-year invasive DFS among patients with HER2-positive early breast cancer, according to study results presented at ASCO Annual Meeting.

Kristin E. Rojas, MD, FACS, FACOG, is working to shed light on and address the multifaceted needs of female patients with cancer and survivors, including sexual dysfunction, with the Menopause Urogenital Sexual Health and Intimacy Clinic.